Le Lézard
Classified in: Health
Subjects: NPT, SVY, BFA

LUNGevity Foundation Kicks Off New Public Service Campaign to Alter View Of Lung Cancer Diagnosis


WASHINGTON, Jan. 18, 2018 /PRNewswire/ -- LUNGevity, the nation's leading lung cancer-focused nonprofit organization, has launched a new awareness campaign to change the common perception of a lung cancer diagnosis. The campaign, Inhale For Life, utilizes video, social media, and a digital billboard in Times Square, NYC, to reach those living with lung cancer with the message that thanks to new treatment options ? particularly biomarker driven therapeutics and immunotherapy, people today are living longer and better with the disease.

Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8118151-lungevity-foundation-lung-cancer-psa-inhale-for-life/

Inhale for Life uses breathing to represent the connection between all of us ? lung cancer patients and non-patients alike. Close-ups of a wide variety of healthy-looking people are shown inhaling; some are then revealed to be lung cancer survivors.  The campaign upends the ominous vision of lung cancer patients portrayed for decades in ads.

Lung cancer is the second most commonly diagnosed cancer worldwide, with more than 1.8 million new cases diagnosed each year. 1 in 16 Americans will have a lung cancer diagnosis in their lifetime. Nearly 65% of new diagnoses are nonsmokers, most often found late when the disease is stage 3 or 4 and more difficult to treat. Just a few years ago, late-stage patients had few treatment options. Today, due to accelerated advancements in research, this is changing, and many late-stage patients are living longer and better lives.

"Many people don't know that real advances have been made in treating lung cancer," said Andrea Ferris, President of LUNGevity Foundation. "Our goal with Inhale For Life is to reach those affected by lung cancer with the message that they should seek out options and never give up hope. We look forward to the day when lung cancer is treated as a chronic illness." 

Inhale for Life was launched through social media to coincide with Lung Cancer Awareness Month in November, supported in part by grants from Genentech and AstraZeneca. In its first three weeks alone, the video has been viewed by over 120,000 people, with hundreds signing up to learn more.  A ten-second version of the public service announcement is now appearing before holiday crowds on a digital billboard in Times Square, made possible through a grant from Bristol-Myers Squibb.

About Lung Cancer:

About LUNGevity Foundation:
LUNGevity Foundation is firmly committed to making an immediate impact on increasing quality of life and survivorship of people with lung cancer by accelerating research into early detection and more effective treatments, as well as by providing community, support, and education for all those affected by the disease. Our vision is a world where no one dies of lung cancer. For more information about LUNGevity Foundation, please visit www.LUNGevity.org.

 

SOURCE LUNGevity Foundation


These press releases may also interest you

at 07:45
The "Laboratory Filtration Equipment - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. Global Laboratory Filtration Equipment Market to Reach $3 Billion by 2030 The global market for Laboratory...

at 07:40
The "Global Weight Loss Drugs Market: Analysis By Product Type, By Drug Type, By Distribution Channel, By End User, By Region, Size and Trends with Impact of COVID-19 and Forecast up to 2029" report has been added to ResearchAndMarkets.com's...

at 07:35
Arrowhead Pharmaceuticals, Inc. today announced its plan to host a 2024 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company's proprietary Targeted RNAi Molecule...

at 07:35
Reports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These Results Include an Unfavorable Impact of $0.08 Per Share Related to Acquired IPR&D and...

at 07:30
During an awards ceremony to present the 2024 list of Best Workplacestm in Canada, Great Place to Work® announced the 50 Best Workplacestm in Canada with 100-999 employees....

at 07:05
At the ESCMID Global 2024 conference, Bruker is enhancing its innovative diagnostic solutions in microbial identification, antimicrobial susceptibility testing (AST), early sepsis diagnostics, and other infectious disease assays. Simplifying...



News published on and distributed by: